| Title: | LIPID-LOWERING THERAPY FOR ASCVD: GUIDELINES AND AGENTS |
| Topic: | Cardiology |
| Relevant Terms: | Lipid management; cardiovascular disease; athersclerosis; familial hypercholesterolemia; dyslipidemia |
| Primary Audience: | Primary Care Physicians; Nurse Practitioners; Physician Assistants |
| Launch Date: | 04-Aug-16 |
| Credits: | 0.75 AMA PRA Category 1 Credit™ |
| Expiration Date: | 04-Aug-17 |
| Curriculum Name: | Achieving LDL Goals in Patients with Hypercholesterolemia |
LEARNING OBJECTIVES
After completing this activity, the participant will demonstrate the ability to:
- Discuss the limitations of currently available lipid-lowering agents and the need for novel treatment options
- Describe the mechanism of action, efficacy and safety of PCSK9 inhibitors and what differentiates them from other forms of lipid-lowering therapy
- Review the clinical trial data supporting the use of PCSK9 inhibitors to lower LDL cholesterol and ongoing outcomes trials in at-risk patients with hypercholesterolemia
- Apply current evidence-based therapies to optimize control of LDL-C in patients with hypercholesterolemia
+++++++++++++++++++++++++++++++++++++++++++++++++++++++
the CMECompanion will alert you when new activities become available that are relevant to your specialty. Please take a moment to review the activity list below. We hope you find it to be valuable to your CME work.
No comments:
Post a Comment